Search results
Jan 13, 2017 · Early preclinical work has shown that when the human Scbeta cells are transplanted into mice, they show high levels of human insulin in their blood after a glucose challenge. In animal models, they have been shown to effectively control diabetes.
Dec 2, 2015 · Semma Therapeutics focuses on diabetes research that uses stem cells in an effort to cure the disease. The company is built on research that came out of Doug Melton’s laboratory at the Harvard Stem Cell Institute, where Melton and his team, including Semma’s scientific co-founder Felicia Pagliuca, were able to generate beta cells in a petri ...
Sep 3, 2019 · Implantation of the islet cell-filled device has the potential to replace the missing beta cells in a diabetic patient without requiring patient immunosuppression. Semma is working to bring this new therapeutic option to the clinic and improve the lives of patients with diabetes.
Sep 3, 2019 · Vertex said Tuesday it will pay $950 million in cash for a preclinical biotech researching a cure for Type 1 diabetes. Since its 2014 founding, Semma Therapeutics has worked on a stem cell-based therapy for Type 1 diabetes, publishing preclinical proof-of-concept data earlier this year.
Dec 4, 2017 · Why is this story important? The successful completion of $114 million in Series B financing by Semma Therapeutics promises to have a big impact on potential expansion of Semma Therapeutics’ operations in Rhode Island. The questions that need to be asked.
Oct 18, 2021 · The treatment is designed to restore the body’s ability to regulate glucose by giving patients new insulin-producing pancreatic islet cells based on donor stem cells. The hope is to replace the...
People also ask
Who owns Semma Therapeutics?
What does Semma do?
Can Semma treat type 1 diabetes?
Sep 4, 2019 · Vertex Pharmaceutics has announced it has entered into a definitive agreement to acquire Semma Therapeutics for $950m. Semma is an early-stage biotech that is developing stem cell therapies for type 1 diabetes patients; the deal with introduce a new disease area into Vertex’s pipeline.
